The Evolving Treatment Paradigm for Chronic Spontaneous Urticaria Management - Episode 5
Remibrutinib for CSU Treatment
A panelist discusses the potential of remibrutinib as an effective oral alternative to omalizumab for chronic spontaneous urticaria (CSU), noting its rapid onset, promising trial results, and anticipated use in patients who prefer oral therapy or have not responded to biologics.
The speaker shares their involvement in the clinical trials for remibrutinib, an oral therapy for CSU. The drug demonstrated a reduction in urticaria activity at 12 weeks that was comparable to the standard of care, omalizumab. A key advantage of remibrutinib is its oral formulation, which offers convenience, and it shows a rapid onset of action, similar to that of omalizumab and other emerging therapies. However, there is still limited experience with remibrutinib, particularly in specific populations such as women who may be pregnant or planning pregnancy.
Looking ahead, the clinician plans to first use remibrutinib in patients who have not responded fully to omalizumab or who have experienced omalizumab treatment failure altogether. Additionally, it may be a strong option for patients who prefer an oral treatment over injectable biologics. This approach will allow for early assessment of the drug’s performance in real-world settings, helping to gauge how well its clinical trial results translate into everyday practice.
If remibrutinib proves to be as effective in practice as it was in trials, it is expected to become a routine alternative to omalizumab in the CSU treatment algorithm. Ultimately, offering it alongside existing options would empower patients to choose a therapy that best fits their preferences and needs, improving patient satisfaction and potentially treatment adherence.
